GENENTA SCIENCE SPA - ADR
GNTANASDAQ🏆 #3535 by market capUS Equity
$573.63▲ $14.46 (+2.52%)
Simulated price1h—
24h▲ 2.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$35M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
57
Weak
No chart data available for GNTA.
Trading Snapshot
- Day Range
- $565.06 – $578.56
- 52-Week Range
- —
- Volume
- $3.04B
- Avg Volume
- $2.36B
- Shares Outstanding
- 23.6M
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own GNTA
- ✓High-growth profile — revenue up +42.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$4M▲ +49.5% YoY
Gross Margin (TTM)
26.6%▲ +0.2% YoY
Operating Income (TTM)
$685,960▲ +49.5% YoY
Free Cash Flow (TTM)
$250,639▲ +49.5% YoY
About GENENTA SCIENCE SPA - ADR
A company profile for GENENTA SCIENCE SPA - ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
57/100
Analyst Price Target
ⓘAverage Target
$750.49
▲ +30.8% Upside
High Target$860.95
Low Target$616.47
Based on 36 analysts
Latest News & Updates
🚀
CNBC·2h ago
GENENTA SCIENCE SPA - ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift GNTA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
GENENTA SCIENCE SPA - ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.